

# The efficacy and safety of monotherapy in moderate to severe atopic dermatitis

## PURPOSE OF THIS STUDY:

To assess the efficacy of PF-04965842 compared with placebo in subjects aged 18 years and older with moderate to severe atopic dermatitis (AD).

## WHO CAN PARTICIPATE?

- Patients aged 18 years or older with moderate to severe atopic dermatitis with a minimum body weight of 40kg
- Diagnosis of AD for at least 1 year and current status of moderate to severe disease
- Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control

## WHAT IS INVOLVED?

- Participation will be for approximately 20 weeks
- Physical exams, blood tests, ECG, and questionnaires are some of the tests involved if you choose to participate in the study

## CONTACT INFORMATION:

Grace Mak, Study Coordinator  
Phone: 604.875.5296  
Email: [grace.mak@ubc.ca](mailto:grace.mak@ubc.ca)

## STUDY TIME/DURATION

Ongoing

## STUDY LOCATION

Clinical Trials Unit  
Skin Care Centre  
UBC Department of  
Dermatology and Skin  
Science  
835 West 10th Avenue  
Vancouver

## PRINCIPAL INVESTIGATOR

Dr. Vincent Ho  
Department of Dermatology  
and Skin Science, UBC  
Research Investigator with  
VCH Research Institute

To learn more about this study, visit [vchri.ca/participate](http://vchri.ca/participate)



**Health research changes lives.**

Be part of the discovery.  
[vchri.ca/participate](http://vchri.ca/participate)

Vancouver  
CoastalHealth  
Research Institute